Home » Stocks » KTRA

Kintara Therapeutics, Inc. (KTRA)

Stock Price: $1.39 USD -0.18 (-11.46%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $1.43 +0.04 (2.88%) Apr 16, 7:37 PM
Market Cap 42.57M
Revenue (ttm) n/a
Net Income (ttm) -33.91M
Shares Out 24.85M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.39
Previous Close $1.57
Change ($) -0.18
Change (%) -11.46%
Day's Open 1.53
Day's Range 1.38 - 1.54
Day's Volume 406,826
52-Week Range 0.50 - 3.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Kintara Therapeutics Inc (NASDAQ:KTRA) has announced interim data from two Phase 2 clinical trials of its lead compound, VAL-083 for glioblastoma multiforme (GBM), which continue to demonstrate its pote...

6 days ago - Proactive Investors

10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX)  presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...

Other stocks mentioned: ALT, AUIAF, AURQF, AUSAF, BABYF, CAAOF, CRTPF ...
6 days ago - Proactive Investors

SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are faili...

6 days ago - PRNewsWire

Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021.  Kintara Therapeutics, Inc. (NASDAQ: KTRA) a biopharm...

1 week ago - Benzinga

SAN DIEGO, March 10, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapi...

1 month ago - PRNewsWire

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) has hired cancer expert Dr Mario Lacouture to its Cutaneous Metastatic Breast Cancer (CMBC)-focused scientific advisory board.  It comes as the company p...

1 month ago - Proactive Investors

Kintara Therapeutics Inc (NASDAQ: KTRA) has enrolled the final patient in the recurrent arm of its ongoing Phase 2 study evaluating VAL-083 for glioblastoma multiforme, the most aggressive form of brain...

2 months ago - Benzinga

Kintara Therapeutics Inc (NASDAQ:KTRA) announced Wednesday that it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme (GBM) study of its VAL-083 ...

2 months ago - Proactive Investors

Kintara Therapeutics Inc (NASDAQ:KTRA), the cancer-focused biopharma, said it has enough cash to fund its planned operations into the fourth quarter of calendar 2021, as the company posted its second-qu...

2 months ago - Proactive Investors

Kintara Therapeutics (NASDAQ:KTRA) is currently down 7.64% to a price of $2.46. The stock's volume is currently 77.04 thousand, which is roughly 4.66% of its recent 30-day volume average of 1.66 million.

2 months ago - Benzinga

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...

5 months ago - PRNewsWire

SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has entered into definitiv...

7 months ago - PRNewsWire

SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has regained compliance w...

7 months ago - PRNewsWire

About KTRA

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Saiid Zarrabian
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
KTRA
Full Company Profile

Financial Performance

Financial Statements